These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8163364)

  • 21. Progressive muscle relaxation reduces migraine frequency and normalizes amplitudes of contingent negative variation (CNV).
    Meyer B; Keller A; Wöhlbier HG; Overath CH; Müller B; Kropp P
    J Headache Pain; 2016; 17():37. PubMed ID: 27090417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exteroceptive suppression of temporalis muscle activity in various types of headache.
    Paulus W; Raubüchl O; Straube A; Schoenen J
    Headache; 1992 Jan; 32(1):41-4. PubMed ID: 1555931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of climacteric syndrome using Estraderm TTS and premarin in a comparative study].
    Leodolter S; Sainz H; Moll-Schüler I; Mach R
    Gynakol Geburtshilfliche Rundsch; 1992; 32(4):201-4. PubMed ID: 1337708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of migraine attacks using a slow cortical potential, the contingent negative variation.
    Kropp P; Gerber WD
    Neurosci Lett; 1998 Nov; 257(2):73-6. PubMed ID: 9865930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exteroceptive suppression patterns of masseter and temporalis muscles in central and peripheral headache disorders.
    Tataroglu C; Kanik A; Sahin G; Ozge A; Yalçinkaya D; Idiman F
    Cephalalgia; 2002 Jul; 22(6):444-52. PubMed ID: 12133044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM).
    Nappi RE; Terreno E; Sances G; Martini E; Tonani S; Santamaria V; Tassorelli C; Spinillo A
    Contraception; 2013 Sep; 88(3):369-75. PubMed ID: 23453784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Change in the second exteroceptive suppression period of the temporalis muscle during erenumab treatment.
    Rota E; Aguggia M; Immovilli P; Morelli N; Renosio D; Barbanera A
    Naunyn Schmiedebergs Arch Pharmacol; 2022 May; 395(5):607-611. PubMed ID: 35179620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine.
    Elkind AH; MacGregor EA
    Expert Rev Neurother; 2008 May; 8(5):723-36. PubMed ID: 18457529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rizatriptan in the treatment of menstrual migraine.
    Silberstein SD; Massiou H; Le Jeunne C; Johnson-Pratt L; McCarroll KA; Lines CR
    Obstet Gynecol; 2000 Aug; 96(2):237-42. PubMed ID: 10908770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contingent negative variation in patients with chronic daily headache.
    Siniatchkin M; Gerber WD; Kropp P; Vein A
    Cephalalgia; 1998 Oct; 18(8):565-9; discussion 531. PubMed ID: 9827249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of estrogens in skin patches in treatment of pre-menstrual syndrome].
    Liber Z; Spiewankiewicz B; Stelmachów J
    Pol Tyg Lek; 1992 Nov 2-9; 47(44-45):1018-20. PubMed ID: 1305712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nimesulide in the treatment of menstrual migraine.
    Giacovazzo M; Gallo MF; Guidi V; Rico R; Scaricabarozzi I
    Drugs; 1993; 46 Suppl 1():140-1. PubMed ID: 7506154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exteroceptive suppression of temporalis muscle activity: a blind study of tension-type headache, migraine, and cervicogenic headache.
    Zwart JA; Sand T
    Headache; 1995 Jun; 35(6):338-43. PubMed ID: 7635719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurophysiological reactivity before a migraine attack.
    Siniatchkin M; Averkina N; Andrasik F; Stephani U; Gerber WD
    Neurosci Lett; 2006 May; 400(1-2):121-4. PubMed ID: 16540242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous bromocriptine therapy in menstrual migraine.
    Herzog AG
    Neurology; 1997 Jan; 48(1):101-2. PubMed ID: 9008502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contingent negative variation in childhood migraine.
    Besken E; Pothmann R; Sartory G
    Cephalalgia; 1993 Feb; 13(1):42-3. PubMed ID: 8448788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is increased amplitude of contingent negative variation in migraine due to cortical hyperactivity or to reduced habituation?
    Kropp P; Gerber WD
    Cephalalgia; 1993 Feb; 13(1):37-41. PubMed ID: 8448787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome.
    Smith RN; Studd JW; Zamblera D; Holland EF
    Br J Obstet Gynaecol; 1995 Jun; 102(6):475-84. PubMed ID: 7632640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contingent negative variation as indicator of duration of migraine disease.
    Kropp P; Siniatchkin M; Gerber WD
    Funct Neurol; 2000; 15 Suppl 3():78-81. PubMed ID: 11200805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contingent negative variation in headache.
    Maertens de Noordhout A; Timsit-Berthier M; Timsit M; Schoenen J
    Ann Neurol; 1986 Jan; 19(1):78-80. PubMed ID: 3947039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.